Felitan

Felitan tablet is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Take a single 45 mg Fezolinetant tablet orally once daily with or without food. Take Fezolinetant with liquids and swallow whole. Do not cut, crush, or chew tablets. Administer Fezolinetant orally at about the same time each day. If a dose of Fezolinetant is missed or not taken at the usual time, administer the missed dose as soon as possible, unless there is less than 12 hours before the next scheduled dose. Return to the regular schedule the following day.
Pediatric Use
: The efficacy and safety of Fezolinetant in individuals less than 18 years of age have not been established.
Geriatric Use
: There have not been sufficient numbers of geriatric women involved in clinical trials utilizing Fezolinetant to determine whether those over 65 years of age differ from younger women in their response to Fezolinetant.

Common side efects of Felitan include:
stomach (abdominal) pain
diarrhea
difculty sleeping
back pain
hot fashes or hot fushes
Stop Felitan if you have the following signs or symptoms of liver problems:
nausea
vomiting
itching
yellowing of the eyes or skin (jaundice)
pale feces
dark urine
pain in the right upper stomach (abdomen)

Hepatic Transaminase Elevation and Hepatotoxicity: Elevations in serum transaminase concentrations greater than 3 times the upper limit of normal (ULN) occurred in the clinical trials. Perform hepatic laboratory tests prior to initiation of Felitan to evaluate for hepatic function and injury. Patient should not start Felitan if the concentration of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is equal to or exceeds 2 times the ULN or if the total bilirubin is elevated (for example, equal to or exceeds 2 times the ULN) for the evaluating laboratory. Patient should perform follow-up hepatic laboratory tests monthly for the frst 3 months, at 6 months, and 9 months after initiation of therapy.

Fezolinetant is a neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center. Fezolinetant has high affinity for the NK3 receptor (Ki value of 19.9 to 22.1 nmol/L), which is more than 450-fold higher than binding affinity to NK1 or NK2 receptors.
Treatment with fezolinetant did not show any clear trends in sex hormones measured (follicle-stimulating hormone, testosterone, estrogen, and dehydroepiandrosterone sulfate) in menopausal women. Transient decrease of luteinizing hormone (LH) levels was observed at peak concentrations of fezolinetant.